Viewing Study NCT03310541



Ignite Creation Date: 2024-05-06 @ 10:39 AM
Last Modification Date: 2024-10-26 @ 12:33 PM
Study NCT ID: NCT03310541
Status: COMPLETED
Last Update Posted: 2023-05-06
First Post: 2017-10-11

Brief Title: AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: Memorial Sloan Kettering Cancer Center

Study Overview

Official Title: A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1 AKT2 or AKT3
Status: COMPLETED
Status Verified Date: 2023-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will test the recommended dose of AZD5363 recommended from a previous phase 1 study of the drug in patients with specific AKT mutations In patients who have ER positive breast cancer with an AKT mutation they will also be receiving a standard breast cancer drug called fulvestrant that is given as an injection In patients who have prostate cancer with an AKT mutation they will also be receiving a standard prostate cancer drug called enzalutamide that is taken orally
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None